Novartis AG plans to cut around 130 jobs in Switzerland as it relocates laboratory activities and ends small-scale biologics production at its Kleinbasel site in Basel, part of a previously announced plan to establish a new biologics technical development center at its main Basel campus. The company will move laboratories supporting biological cell banks, analytical testing, and technical development to the main campus by the end of 2028, while small-scale production at Kleinbasel is expected to end by the end of 2027. The relocation is tied to individual leases expiring in 2029, and affected production will shift to existing biologics drug-substance facilities elsewhere in Europe. The potential job cuts, affecting roughly 130 of about 200 employees at Kleinbasel, are subject to an information and consultation process, with support measures including job centers, early retirement, and an extended social plan. The move comes alongside a $23 billion investment to build and expand 10 U.S. facilities over five years, and follows positive late-stage results for remibrutinib in relapsing multiple sclerosis, which analysts see as potentially generating billions in annual sales.
Novartis AGJob cuts and consolidation of biologics operations in Basel, reducing local production and workforce.
